UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of December 2023

 

Commission File Number: 001-39591

 

 

  

iHuman Inc.

(Registrant’s Name)

 

 

 

Floor 8, Building B,
No. 1 Wangjing East Road,
Chaoyang District, Beijing 100102

People’s Republic of China

(Address of Principal Executive Offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F x      Form 40-F ¨

 

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Press Release

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  iHuman Inc.
   
       
  By       : /s/ Vivien Weiwei Wang
  Name : Vivien Weiwei Wang
  Title : Director and Chief Financial Officer

 

Date: December 28, 2023

 

 

 

 

Exhibit 99.1

 

 

iHuman Inc. Announces Third Quarter 2023 Unaudited Financial Results

 

BEIJING, China, December 28, 2023 -- iHuman Inc. (NYSE: IH) (“iHuman” or the “Company”), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the third quarter ended September 30, 2023.

 

Third Quarter 2023 Highlights

 

Revenues were RMB261.5 million (US$35.8 million), compared with RMB251.5 million in the same period last year.

Gross profit was RMB186.6 million (US$25.6 million), compared with RMB177.1 million in the same period last year.

Operating income was RMB40.4 million (US$5.5 million), compared with RMB38.5 million in the same period last year.

Adjusted operating income1 was RMB42.9 million (US$5.9 million), compared with RMB42.5 million in the same period last year.

Net income was RMB51.9 million (US$7.1 million), compared with RMB39.5 million in the same period last year.

Adjusted net income1 was RMB54.4 million (US$7.5 million), compared with RMB43.5 million in the same period last year.

Average total MAUs2 reached a record-high of 25.36 million, a year-over-year increase of 22.9%.

 

Dr. Peng Dai, Director and Chief Executive Officer of iHuman, commented, “We are excited to announce another strong quarter of results with average total MAUs increasing an impressive 22.9% year-over-year to reach another record-high of 25.36 million, which I believe reflects our unwavering commitment to delivering exceptional experiences and value to our users.”

 

“During the quarter, we focused squarely on strengthening our product portfolio in both domestic and international markets. Domestically, we further refined our industry-leading offerings with improvements to both content and functionality. We launched two additional exciting themes for iHumanpedia, “Earth Treasure Hunt” and “Animal Architects,” which were specifically designed to nurture the scientific curiosity of children. As we continue to expand our content library, we are constantly developing innovative ways to engage users and enrich their experiences. For example, we hosted popular science competitions that encouraged participants to create science-themed short-form videos, among which the most outstanding entries would be featured on the iHumanpedia app. These initiatives as well as others we have rolled out all received enthusiastic feedback from users and are encouraging more active participation and contributing to a more vibrant community.”

 

“Internationally, we enhanced the appeal of our products by rolling out popular seasonal themes that resonate with overseas users. For example, we launched a Halloween pack for Aha World which offered a wide selection of classic Halloween costumes and immersive, spooky experiences that were highly popular among younger audiences. Aha World has recently surged to rank among the top three most popular children’s apps on Apple’s app store in the U.S. These ongoing efforts to drive product excellence are increasingly earning us international recognition. Notably, we were awarded the prestigious w3 Gold Award in the Mobile Apps & Sites - Family & Kids category, for bekids Reading. With thousands of entries from across the globe annually, the w3 Awards is one of the most prestigious honors in digital design, marketing, media and technology that recognizes the industry’s best across user experiences, content, and creativity. Winning the w3 Gold Award represents a substantial recognition of the high quality and innovative nature of our products and marks another significant milestone for us as a company specialized in child intellectual development.”

 

 

1 “Adjusted operating income” and “adjusted net income” exclude share-based compensation expenses. Please see “Non-GAAP Financial Measures” and “Unaudited Reconciliation of GAAP and non-GAAP Results” at the end of this press release.

2 “Average total MAUs” refers to the monthly average of the sum of the MAUs of each of the Company’s apps during a specific period, which is counted based on the number of unique mobile devices through which such app is accessed at least once in a given month, and duplicate access to different apps is not eliminated from the total MAUs calculation.

 

1

 

 

“Our smart devices business also continued to make solid progress with the launch of the second generation of Logic Pal, an easy-to-operate device designed to facilitate early childhood word recognition, pronunciation, and cognitive growth through pluggable cards and interactive activities. To diversify our offerings, we have also launched Diandian Storyteller, a portable device that empowers children to enhance their storytelling abilities and expand their imagination.”

 

“We are truly encouraged by the momentum across our entire portfolio and take great pride in our team’s resolve and consistent execution. I am excited about the opportunities that lie ahead and the potential for our continuous growth and innovation,” concluded Dr. Dai.

 

Ms. Vivien Weiwei Wang, Director and Chief Financial Officer of iHuman, added, “With an unwavering focus on long-term growth, we continue to invest in refining our product lineup while steadily expanding our overseas presence. Our dedication and relentless efforts to the business have enabled us to achieve another solid quarter. We once again recorded revenue growth on both an annual and sequential basis, marking our seventh consecutive profitable quarter. This remarkable achievement has further solidified our financial position, establishing a solid foundation for our future expansion.”

 

“While we continue to advance our strategic priorities, we are also actively engaged in public initiatives that aim to inspire young minds and support their holistic development. Since the launch of bekids Coding, we have been enthusiastic participants in the Hour of Code, a global initiative that introduces tens of millions of students worldwide to computer science and programming through free coding tutorials and activities. In 2022, several elementary schools across the United States completed our Hour of Code challenge and shared their experiences on social media. This year, we are thrilled to participate in the Hour of Code initiative again, aiming to further inspire and engage children worldwide. Our participation in such events has strengthened our brand profile and influence internationally. As we move forward, our commitment to managing a strong portfolio of products and driving business growth will remain central to our strategy, ensuring sustainable development and creating more value for our shareholders.”

 

Third Quarter 2023 Unaudited Financial Results

 

Revenues

 

Revenues were RMB261.5 million (US$35.8 million), an increase of 4.0% from RMB251.5 million in the same period last year, primarily driven by user expansion and enhanced user engagement.

 

Average total MAUs for the quarter were 25.36 million, an increase of 22.9% year-over-year from 20.63 million in the same period last year. The number of paying users3 was 1.54 million.

 

Cost of Revenues

 

Cost of revenues was RMB74.9 million (US$10.3 million), maintaining approximately the same level of RMB74.4 million in the same period last year.

 

Gross Profit and Gross Margin

 

Gross profit was RMB186.6 million (US$25.6 million), an increase of 5.4% from RMB177.1 million in the same period last year. Gross margin was 71.4%, compared with 70.4% in the same period last year.

 

Operating Expenses

 

Total operating expenses were RMB146.2 million (US$20.0 million), an increase of 5.5% from RMB138.6 million in the same period last year.

 

 

3 “Paying users” refers to users who paid subscription fees for premium content on any of the Company’s apps during a specific period; a user who makes payments across different apps using the same registered account is counted as one paying user, and a user who makes payments for the same app multiple times in the same period is counted as one paying user.

 

2

 

 

Research and development expenses were RMB66.2 million (US$9.1 million), a decrease of 7.9% from RMB71.9 million in the same period last year, primarily due to payroll-related cost savings and decreased outsourcing expenses as a result of the continued optimization of our operational efficiency.

 

Sales and marketing expenses were RMB54.0 million (US$7.4 million), an increase of 29.6% from RMB41.7 million in the same period last year, primarily due to increased strategic spending on promotional activities.

 

General and administrative expenses were RMB26.1 million (US$3.6 million), compared with RMB25.0 million in the same period last year.

 

Operating Income

 

Operating income was RMB40.4 million (US$5.5 million), compared with RMB38.5 million in the same period last year.

 

Excluding share-based compensation expenses, adjusted operating income was RMB42.9 million (US$5.9 million), compared with RMB42.5 million in the same period last year.

 

Net Income

 

Net income was RMB51.9 million (US$7.1 million), an increase of 31.5% from RMB39.5 million in the same period last year.

 

Adjusted net income was RMB54.4 million (US$7.5 million), an increase of 25.1% from RMB43.5 million in the same period last year.

 

Basic and diluted net income per ADS were RMB0.98 (US$0.13) and RMB0.95 (US$0.13), respectively, compared with RMB0.74 and RMB0.73 in the same period last year. Each ADS represents five Class A ordinary shares of the Company.

 

Adjusted diluted net income per ADS was RMB0.99 (US$0.14), compared with RMB0.80 in the same period last year.

 

Deferred Revenue and Customer Advances

 

Deferred revenue and customer advances were RMB320.4 million (US$43.9 million) as of September 30, 2023, compared with RMB379.1 million as of December 31, 2022.

 

Cash, Cash Equivalents and Time Deposits

 

Cash, cash equivalents and time deposits were RMB1,174.2 million (US$160.9 million) as of September 30, 2023, compared with RMB1,050.0 million as of December 31, 2022.

 

Extension of Share Repurchase Program

 

Given its confidence in the Company's business prospects, the board of directors (the “Board”) has authorized another extension of the Company’s existing share repurchase program, as authorized in December 2021 and extended in December 2022, by twelve months through December 31, 2024. Pursuant to the extended share repurchase program, the Company’s proposed repurchases may be made from time to time through open market transactions at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on the market conditions and in accordance with applicable rules and regulations. The timing and dollar amount of repurchase transactions will be subject to the Securities and Exchange Commission Rule 10b-18 and Rule 10b5-1 requirements. The Board will continue to review the extended share repurchase program periodically, and may authorize adjustments to its terms and size. The Company expects to continue to fund the repurchases under the extended share repurchase program with its existing cash balance.

 

3

 

 

Exchange Rate Information

 

The U.S. dollar (US$) amounts disclosed in this press release, except for those transaction amounts that were actually settled in U.S. dollars, are presented solely for the convenience of the reader. The conversion of Renminbi (RMB) into US$ in this press release is based on the exchange rate set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System as of September 29, 2023, which was RMB7.2960 to US$1.00. The percentages stated in this press release are calculated based on the RMB amounts.

 

Non-GAAP Financial Measures

 

iHuman considers and uses non-GAAP financial measures, such as adjusted operating income, adjusted net income and adjusted diluted net income per ADS, as supplemental metrics in reviewing and assessing its operating performance and formulating its business plan. The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). iHuman defines adjusted operating income, adjusted net income and adjusted diluted net income per ADS as operating income, net income and diluted net income per ADS excluding share-based compensation expenses, respectively. Adjusted operating income, adjusted net income and adjusted diluted net income per ADS enable iHuman’s management to assess its operating results without considering the impact of share-based compensation expenses, which are non-cash charges. iHuman believes that these non-GAAP financial measures provide useful information to investors in understanding and evaluating the Company’s current operating performance and prospects in the same manner as management does, if they so choose.

 

Non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. Non-GAAP financial measures have limitations as analytical tools, which possibly do not reflect all items of expense that affect our operations. Share-based compensation expenses have been and may continue to be incurred in our business and are not reflected in the presentation of the non-GAAP financial measures. In addition, the non-GAAP financial measures iHuman uses may differ from the non-GAAP measures used by other companies, including peer companies, and therefore their comparability may be limited. The presentation of these non-GAAP financial measures is not intended to be considered in isolation from or as a substitute for the financial information prepared and presented in accordance with GAAP.

 

Safe Harbor Statement

 

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Statements that are not historical facts, including statements about iHuman’s beliefs and expectations, are forward-looking statements. Among other things, the description of the management’s quotations in this announcement contains forward-looking statements. iHuman may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: iHuman’s growth strategies; its future business development, financial condition and results of operations; its ability to continue to attract and retain users, convert non-paying users into paying users and increase the spending of paying users, the trends in, and size of, the market in which iHuman operates; its expectations regarding demand for, and market acceptance of, its products and services; its expectations regarding its relationships with business partners; general economic and business conditions; regulatory environment; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in iHuman’s filings with the SEC. All information provided in this press release is as of the date of this press release, and iHuman does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

 

About iHuman Inc.

 

iHuman Inc. is a leading provider of tech-powered, intellectual development products in China that is committed to making the child-upbringing experience easier for parents and transforming intellectual development into a fun journey for children. Benefiting from a deep legacy that combines over two decades of experience in the parenthood industry, superior original content, advanced high-tech innovation DNA and research & development capabilities with cutting-edge technologies, iHuman empowers parents with tools to make the child-upbringing experience more efficient. iHuman’s unique, fun and interactive product offerings stimulate children’s natural curiosity and exploration. The Company’s comprehensive suite of innovative and high-quality products include self-directed apps, interactive content and smart devices that cover a broad variety of areas to develop children’s abilities in speaking, critical thinking, independent reading and creativity, and foster their natural interest in traditional Chinese culture. Leveraging advanced technological capabilities, including 3D engines, AI/AR functionality, and big data analysis on children’s behavior & psychology, iHuman believes it will continue to provide superior experience that is efficient and relieving for parents, and effective and fun for children, in China and all over the world, through its integrated suite of tech-powered, intellectual development products.

 

4

 

 

For more information about iHuman, please visit https://ir.ihuman.com/.

 

For investor and media enquiries, please contact:

 

iHuman Inc.

Mr. Justin Zhang

Investor Relations Director

Phone: +86 10 5780-6606

E-mail: ir@ihuman.com

 

Christensen

In China

Ms. Alice Li

Phone: +86-13381389369

E-mail: alice.li@christensencomms.com

 

In the US

Ms. Linda Bergkamp

Phone: +1-480-614-3004

E-mail: linda.bergkamp@christensencomms.com

 

5

 

 

iHuman Inc.

 

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

 

(Amounts in thousands of Renminbi (“RMB”) and U.S. dollars (“US$”)

except for number of shares, ADSs, per share and per ADS data)

 

   December 31,   September 30,   September 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
ASSETS               
Current assets               
Cash and cash equivalents   1,049,999    1,037,751    142,236 
Time deposits   -    136,416    18,697 
Accounts receivable, net   79,614    69,381    9,509 
Inventories, net   19,127    13,457    1,844 
Amounts due from related parties   2,286    1,979    271 
Prepayments and other current assets   102,765    83,999    11,513 
Total current assets   1,253,791    1,342,983    184,070 
Non-current assets               
Property and equipment, net   9,205    6,530    895 
Intangible assets, net   24,872    24,093    3,302 
Operating lease right-of-use assets   12,782    4,056    556 
Long-term investment   26,333    26,333    3,609 
Other non-current assets   6,416    7,843    1,076 
Total non-current assets   79,608    68,855    9,438 
Total assets   1,333,399    1,411,838    193,508 
                
LIABILITIES               
Current liabilities               
Accounts payable   24,206    16,235    2,225 
Deferred revenue and customer advances   379,063    320,438    43,920 
Amounts due to related parties   6,944    10,917    1,496 
Accrued expenses and other current liabilities   144,717    131,722    18,054 
Current operating lease liabilities   6,123    1,818    249 
Total current liabilities   561,053    481,130    65,944 
Non-current liabilities               
Non-current operating lease liabilities   2,894    2,361    324 
Total non-current liabilities   2,894    2,361    324 
Total liabilities   563,947    483,491    66,268 
SHAREHOLDERS’ EQUITY               
Ordinary shares (par value of US$0.0001 per share, 700,000,000 Class A shares authorized as of December 31, 2022 and September 30, 2023; 125,122,382 Class A shares issued and 121,722,467 outstanding as of December 31, 2022; 125,122,382 Class A shares issued and 119,698,967 outstanding as of September 30, 2023; 200,000,000 Class B shares authorized, 144,000,000 Class B ordinary shares issued and outstanding as of December 31, 2022 and September 30, 2023; 100,000,000 shares (undesignated) authorized, nil shares (undesignated) issued and outstanding as of December 31, 2022 and September 30, 2023)   185    185    25 
Additional paid-in capital   1,079,099    1,086,502    148,917 
Treasury stock   (7,123)   (16,665)   (2,284)
Statutory reserves   7,967    7,967    1,092 
Accumulated other comprehensive income   10,497    23,895    3,275 
Accumulated deficit   (321,173)   (173,537)   (23,785)
Total shareholders’ equity   769,452    928,347    127,240 
Total liabilities and shareholders’ equity   1,333,399    1,411,838    193,508 

 

6

 

 

iHuman Inc.

 

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

(Amounts in thousands of Renminbi (“RMB”) and U.S. dollars (“US$”)

except for number of shares, ADSs, per share and per ADS data)

 

   For the three months ended   For the nine months ended 
   September 30,   June 30,   September 30,   September 30,   September 30,   September 30,   September 30, 
   2022   2023   2023   2023   2022   2023   2023 
   RMB   RMB   RMB   US$   RMB   RMB   US$ 
Revenues   251,527    240,993    261,496    35,841    724,813    767,692    105,221 
Cost of revenues   (74,422)   (70,160)   (74,871)   (10,262)   (214,636)   (224,667)   (30,793)
                                    
Gross profit   177,105    170,833    186,625    25,579    510,177    543,025    74,428 
                                    
Operating expenses                                   
Research and development expenses   (71,859)   (63,412)   (66,168)   (9,069)   (246,685)   (191,253)   (26,213)
Sales and marketing expenses   (41,669)   (40,564)   (53,994)   (7,400)   (111,105)   (134,993)   (18,502)
General and administrative expenses   (25,035)   (25,982)   (26,070)   (3,573)   (79,942)   (78,787)   (10,799)
Total operating expenses   (138,563)   (129,958)   (146,232)   (20,042)   (437,732)   (405,033)   (55,514)
Operating income   38,542    40,875    40,393    5,537    72,445    137,992    18,914 
Other income, net   9,611    8,132    19,507    2,674    15,875    33,721    4,622 
Income before income taxes   48,153    49,007    59,900    8,211    88,320    171,713    23,536 
Income tax expenses   (8,675)   (6,933)   (7,984)   (1,094)   (13,934)   (24,077)   (3,300)
Net income   39,478    42,074    51,916    7,117    74,386    147,636    20,236 
                                    
Net income per ADS:                                   
- Basic   0.74    0.80    0.98    0.13    1.39    2.79    0.38 
- Diluted   0.73    0.77    0.95    0.13    1.38    2.70    0.37 
                                    
Weighted average number of ADSs:                                
- Basic   53,240,710    52,804,594    52,747,426    52,747,426    53,341,120    52,834,352    52,834,352 
- Diluted   54,114,651    54,725,528    54,772,536    54,772,536    54,043,728    54,753,124    54,753,124 
                                    
Total share-based compensation expenses included in:                           
Cost of revenues   77    70    67    9    180    235    32 
Research and development expenses   2,045    1,142    1,160    159    3,813    2,940    403 
Sales and marketing expenses   698    59    147    20    1,040    585    80 
General and administrative expenses   1,187    1,160    1,105    151    2,963    3,557    488 

 

7

 

 

iHuman Inc.

 

UNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS

 

(Amounts in thousands of Renminbi (“RMB”) and U.S. dollars (“US$”)

except for number of shares, ADSs, per share and per ADS data)

 

   For the three months ended   For the nine months ended 
   September 30,   June 30,   September 30,   September 30,   September 30,   September 30,   September 30, 
   2022   2023   2023   2023   2022   2023   2023 
   RMB   RMB   RMB   US$   RMB   RMB   US$ 
Operating income   38,542    40,875    40,393    5,537    72,445    137,992    18,914 
Share-based compensation expenses   4,007    2,431    2,479    339    7,996    7,317    1,003 
Adjusted operating income   42,549    43,306    42,872    5,876    80,441    145,309    19,917 
                                    
Net income   39,478    42,074    51,916    7,117    74,386    147,636    20,236 
Share-based compensation expenses   4,007    2,431    2,479    339    7,996    7,317    1,003 
Adjusted net income   43,485    44,505    54,395    7,456    82,382    154,953    21,239 
                                    
Diluted net income per ADS   0.73    0.77    0.95    0.13    1.38    2.70    0.37 
Impact of non-GAAP adjustments   0.07    0.04    0.04    0.01    0.14    0.13    0.02 
Adjusted diluted net income per ADS   0.80    0.81    0.99    0.14    1.52    2.83    0.39 
                                    
Weighted average number of ADSs – diluted   54,114,651    54,725,528    54,772,536    54,772,536    54,043,728    54,753,124    54,753,124 
Weighted average number of ADSs – adjusted   54,114,651    54,725,528    54,772,536    54,772,536    54,043,728    54,753,124    54,753,124 

 

8

 


iHuman (NYSE:IH)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more iHuman Charts.
iHuman (NYSE:IH)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more iHuman Charts.